Apoptosis in human breast and gastrointestinal carcinomas. Detection in histological sections with monoclonal antibody to single-stranded DNA

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 1979-1988

  Frankfurt, Oskar S ^a   Robb, James A ^a   Sugarbaker, Everett V ^a   Villa, Luis ^a  

^a Cedars Medical Center Miami   (United States)

Author keywords

Apoptosis; bcl 2 oncogene; Breast cancer

Indexed keywords

DNA ANTIBODY; MONOCLONAL ANTIBODY; SINGLE STRANDED DNA;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL CYCLE S PHASE; CELL PROLIFERATION; COLON ADENOCARCINOMA; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; TISSUE SECTION;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; APOPTOSIS; BIOPSY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COLONIC NEOPLASMS; DNA, NEOPLASM; DNA, SINGLE-STRANDED; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, FLUORESCENCE; NECROSIS; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0029783628     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Del Vecchio MT, Leoncini L, Bverki K, Kraft R, Megha T, Barbini P. Tost P and Cottier H: Diffuse centrocytic and/or centroblastic malignant non-Hodgkin's lymphomas: comparison of mitotic and pycnotic (apoptotic) indices. Int J Cancer 47: 38-43, 1991.
2. Lipponen PK and Aaltomaa S: Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 173: 333-339. 1994.
3. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT and Thompson TC: Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Human Pathol 25: 797-801, 1994.
4. Gavrieli Y, Sheeman Y and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992.
5. Ansari B, Coates PJ, Greenstein BD and Mall PA: In situ end-labeling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170: 1-8, 1993.
6. Gold R, Schmied M, Giegerich G, Breitschopf H, Martung HP, Toyka KV and Lassmann H: Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 71: 219-225, 1994.
7. Grasl-Kraupp B, Ruttkay-Nedecy B, Koudelka H, Bukowska K, Bursch W and Schulte-Hermann R: In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis and autolytic cell death: a cautionary note. Hepatol 21: 1465-1468, 1995.
8. Desjardins LM and Macmanus JP: An adherent cell model to study different stages of apoptosis. Exp Cell Res 216: 380-387, 1995.
9. Collins RJ, Harmon BV, Gobe GC and Kerr JFR: Internucleosomal DNA cleavage should not be the sole criterion for identifying apoptosis. Int J Radiat Biol 61: 451453, 1992.
10. Ormerod MG, Neill CF, Robertson D and Harrap KR: Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exper Cell Res 211: 231-237, 1994.
11. Frankfurt OS: Detection of apoptosis in leukemic and breast cancer cells with monoclonal antibody to single-stranded DNA. Anticancer Res 14: 1861-1870, 1994.
12. Frankfurt OS, Seckinger D and Sugarbaker EV: Pleiotropic drug resistance and survival advantage in leukemic cells with diminished apoptotic response. Int J Cancer 59; 217-224, 1994.
13. Frankfurt OS, Seckinger D and Sugarbaker EV: Apoptosis and growth inhibition in sensitive and resistant leukemic cells treated with anticancer drugs. Int J Oncol 4: 481-489, 1994.
14. Frankfurt OS, Sugarbaker EV, Robb JA and Villa L: Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett 97: 149-154, 1995.
15. Frankfurt OS, Byrnes JJ, Seckinger D and Sugarbaker EV: Apoptosis (programmed cell death) and the evaluation of chemosensitivity in chronic lymphocytic leukemia and lymphoma. Oncol Res 5: 37-42, 1993.
16. Frankfurt OS: Decreased stability of DNA in cells treated with alkylating agents. Exp Cell Res 191: 181-185, 1990.
17. Eichhorn GL: Metal ions as stabilizers or destabilizers of DNA structure. Nature 194: 474-475, 1962.
18. Arends MJ, Morris RG and Wyllie AH: Apoptosis. The role of the endonuclease. Am J Pathol 136: 593-608, 1990.
19. Leek RD, Kaklamanis L, Pezzella F, Gatter KC and Harris AL: bcl-2 in normal human breast and carcinoma. Association with estrogen receptor-positive, epidermal growth factor receptor-negative carcinomas and in situ cancer. Br J Cancer 69: 135139, 1994.
20. Silvestrini R, Verenoni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Fronzo G, Rilke F and Veronesi U. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph nodenegative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
21. Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Verderio P, Pezzella F and Harris AL: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1: 189-198, 1995.
22. Korsmeyer SJ: bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
23. Staunton MJ and Gaffney EF: Carcinoma type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 103: 300-307, 1995.
24. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR and Jones RJ: Inhibition of apoptosis during development of colorectal cancer. Cancer Res 55: 1811-1816, 1995.
25. Desmouliere A, Redard M, Darby I and Gabbiani G: Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 146: 56-66, 1995.
26. Cohen JJ: Programmed cell death in the immune system. Adv Immunol 50: 55-85, 1991.